image credit: Unsplash

Modified COVID-19 vaccines can avoid ‘lengthy’ clinical studies, says MHRA

The new guidance, published by the MHRA alongside international regulatory authorities from Australia, Canada, Singapore and Switzerland, details what information is required to approve modifications to authorised COVID-19 vaccines.

Although ‘time-consuming’ clinical studies won’t be needed, vaccine makers will need to provide robust evidence that an updated vaccine produces an immune response against a new variant.

Read More on Pharma Times